doi:10.3969/j.issn.1004-583X.2024.02.018

Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.02.018

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I2/188

References 40

[1]	Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report:GOLD Executive Summary[J]. Am J Respir Crit Care Med, 2023, 207(7):819-837. doi: 10.1164/rccm.202301-0106PP URL
[2]	Dauriat G, Reynaud-Gaubert M, Cottin V, et al. Severe pulmonary hypertension associated with chronic obstructive pulmonary disease:A prospective French multicenter cohort[J]. J Heart Lung Transplant, 2021, 40(9):1009-1018. doi: 10.1016/j.healun.2021.04.021 URL
[3]	Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43(38):3618-3731. doi: 10.1093/eurheartj/ehac237 pmid: 36017548
[4]	Piccari L, Blanco I, Torralba Y, et al. Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD[J]. Eur Respir J, 2023, 62(1):2300463. doi: 10.1183/13993003.00463-2023 URL
[5]	Klinger JR. Treatment of pulmonary hypertension associated with COPD: Time for another look?[J]. Chest, 2021, 160(2):409-410. doi: 10.1016/j.chest.2021.03.010 pmid: 34366028
[6]	Zhang L, Liu Y, Zhao S, et al. The incidence and prevalence of pulmonary hypertension in the COPD population: A systematic review and meta-analysis[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17:1365-1379. doi: 10.2147/COPD.S359873 URL
[7]	Klinger JR, Wu B, Morland K, et al. Burden of pulmonary hypertension due to chronic obstructive pulmonary disease:Analysis of exacerbations and healthcare resource utilization in the United States[J]. Respir Med, 2023, 219:107412. doi: 10.1016/j.rmed.2023.107412 URL
[8]	Sugarman J, Weatherald J. Management of pulmonary hypertension due to chronic lung disease[J]. Methodist Debakey Cardiovasc J, 2021, 17(2):124-133. doi: 10.14797/ZKUT3813 pmid: 34326932
[9]	张志聪. 黄帝内经灵枢集注[M]. 北京: 北京中医古籍出版社, 2012:278.
[10]	朱震亨. 丹溪心法[M]. 北京: 中国医药科技出版社, 2020:82.
[11]	方漫兮, 钟秀君, 汤杰, 等. 从瘀论治慢性阻塞性肺疾病合并肺动脉高压[J]. 现代中西医结合杂志, 2022, 31(5):645-648.
[12]	唐卓然, 王羽嘉, 刘亚倩, 等. 慢性阻塞性肺疾病血管重塑病机发微[J]. 中华中医药杂志, 2019, 34(8):3398-3400.
[13]	唐雅伦, 马秋晓, 张琼, 等. 从“毒瘀损肺”论治慢性阻塞性肺疾病合并肺动脉高压[J]. 环球中医药, 2022, 15(3):475-478.
[14]	崔力心, 张新宇, 周瑞玲, 等. 基于“血不利则为水”理论探讨慢性阻塞性肺疾病肺血管重塑的病机及治疗[J]. 实用心脑肺血管病杂志, 2023, 31(7):6-10.
[15]	Guan S, Yu P, Cao J, et al. Ginsenoside Rg1 protects against cigarette smoke-induced airway remodeling by suppressing the TGF-β1/Smad3 signaling pathway[J]. Am J Transl Res, 2020, 12(2):493-506. pmid: 32194898
[16]	Guan X, Yuan Y, Wang G, et al. Ginsenoside Rg3 ameliorates acute exacerbation of COPD by suppressing neutrophil migration[J]. Int Immunopharmacol, 2020, 83:106449. doi: 10.1016/j.intimp.2020.106449 URL
[17]	Wang RX, He RL, Jiao HX, et al. Preventive treatment with ginsenoside Rb1 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats and involves store-operated calcium entry inhibition[J]. Pharm Biol, 2020, 58(1):1055-1063. doi: 10.1080/13880209.2020.1831026 URL
[18]	张赛, 田云娜, 宋正阳, 等. 三七总皂苷通过抑制ADAM10/Notch3信号通路改善野百合碱诱导的大鼠肺动脉高压[J]. 生理学报, 2023, 75(4):503-511.
[19]	Li X, Chen K, Shi X, et al. Notoginsenoside R1 restrains the proliferation and migration of airway smooth muscle cells isolated from rats with chronic obstructive pulmonary disease[J]. Inhal Toxicol, 2024:1-13.
[20]	Fang ZF, Fu Y, Peng Y, et al. Citrus peel extract protects against diesel exhaust particle-induced chronic obstructive pulmonary disease-like lung lesions and oxidative stress[J]. Food Funct, 2023, 14(21):9841-9856. doi: 10.1039/D3FO02010J URL
[21]	Yin Q, Wang S, Yang J, et al. Nobiletin attenuates monocrotaline-induced pulmonary arterial hypertension through PI3K/Akt/STAT3 pathway[J]. J Pharm Pharmacol, 2023, 75(8):1100-1110. doi: 10.1093/jpp/rgad045 URL
[22]	刘敏, 王启芝, 刘雨, 等. 复方葶苈子汤改善COPD相关性肺动脉高压大鼠的肺血管重塑的机制研究[J]. 湖南中医药大学学报, 2022, 42(3):380-386.
[23]	伍新诚, 刘雨, 柏正平. 复方葶苈子汤通过调控HMGB1介导的细胞焦亡及免疫失衡治疗COPD相关性肺动脉高压[J]. 中国中药杂志, 2023, 48(11):3055-3065.
[24]	朱张求, 朱洁, 童佳兵, 等. 基于JAK1/STAT3信号通路研究芪白平肺胶囊对COPD继发PAH大鼠的影响[J]. 中华中医药杂志, 2023, 38(1):324-330.
[25]	张璐, 童祥丽, 王小乐, 等. 芪白平肺胶囊通过抑制PI3K/Akt通路促进低氧大鼠肺动脉平滑肌细胞凋亡[J]. 安徽中医药大学学报, 2022, 41(2):55-60.
[26]	李松桃, 李欣奕, 宋云峰, 等. 麻杏芎葶合剂干预肺心病急性发作模型小鼠肺组织重构和肺血管重塑相关因子的表达[J]. 中国组织工程研究, 2021, 25(2):274-280.
[27]	李静, 尤文岗. 疏血通对慢性阻塞性肺疾病合并肺动脉高压患者血清D-二聚体与呼吸功能的影响[J]. 西部医学, 2019, 31(6):940-943+948.
[28]	吴敏, 贺晓燕, 谭钰珍. 参脉注射液联合酚妥拉明治疗COPD合并肺动脉高压的临床疗效[J]. 中南医学科学杂志, 2019, 47(5):469-471+523.
[29]	李佳蔚, 戴姣, 邓群峰, 等. 补阳还五汤治疗“气虚血瘀型”慢性阻塞性肺疾病缓解期合并肺动脉高压的临床研究[J]. 湖南师范大学学报(医学版), 2022, 19(5):48-52.
[30]	郑青秀, 叶威, 刘刚. 补阳还五汤治疗气虚血瘀型慢性阻塞性肺疾病合并肺动脉高压的效果观察[J]. 浙江临床医学, 2022, 24(10):1473-1475.
[31]	郑美梅, 刘小虹, 江勇. 加味千金苇茎汤治疗慢阻肺合并肺动脉高压的疗效及其对VEGF的影响[J]. 广东药科大学学报, 2022, 38(3):64-68.
[32]	王建忠, 卢晨君, 付文杰. 加味茯苓甘草汤联合米力农治疗COPD并肺动脉高压的临床研究[J]. 中西医结合心脑血管病杂志, 2019, 17(4):577-580.
[33]	徐向前, 徐倍琪, 郭晓燕, 等. 加味川芎平喘合剂治疗慢性阻塞性肺疾病稳定期合并肺动脉高压的临床疗效观察[J]. 中华中医药杂志, 2019, 34(7):3338-3340.
[34]	范春香, 陈宝瑾, 陈斌宾, 等. 加味川芎平喘合剂治疗痰瘀阻肺型慢性阻塞性肺疾病急性加重期合并肺动脉高压临床观察[J]. 河北中医, 2020, 42(3):351-354+359.
[35]	何云蕾, 程秉山. 温肺固本活血汤对老年慢性阻塞性肺疾病合并肺动脉高压稳定期患者心肺功能及血浆N末端脑钠肽前体水平的影响[J]. 现代中西医结合杂志, 2020, 29(25):2783-2787.
[36]	赵樱. 补肺化痰活血方对COPD合并肺动脉高压的疗效分析[J]. 浙江临床医学, 2020, 22(10):1458-1460.
[37]	张慧俭, 刘世举. 益气活血补肾汤治疗慢性阻塞性肺疾病合并肺动脉高压气虚证[J]. 中医学报, 2019, 34(12):2635-2640.
[38]	苗同艳, 吴瑞, 张辉, 等. 中医解毒祛瘀法综合治疗慢阻肺合并肺动脉高压痰热蕴肺证47例[J]. 环球中医药, 2023, 16(8):1659-1663.
[39]	刘洁华, 黄灿均. 补肺活血汤配合艾灸治疗COPD合并肺动脉高压的临床观察[J]. 中西医结合研究, 2020, 12(2):91-93.
[40]	区淑娟, 路向东, 郭常庆. 理肺汤联合穴位埋线治疗慢性阻塞性肺疾病合并肺动脉高压稳定期临床研究[J]. 新中医, 2019, 51(1):205-209.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 40

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2023, 38(8): 749-752.
[2]	. [J]. Clinical Focus, 2022, 37(11): 1048-1052.
[3]	Sun Ying, Yu Qin. Long-term effect of hypoglossal nerve stimulation in the treatment of obstructive sleep apnea hypopnea syndrome: A meta analysis [J]. Clinical Focus, 2022, 37(8): 677-684.
[4]	Wang Xuefeng. Clinical correlation between fatigue and multi-dimensional indexes in patients with stable moderate chronic obstructive pulmonary disease [J]. Clinical Focus, 2022, 37(8): 704-707.
[5]	Zhang Zhiping, Zhang Baomin, Qin Wei, Gao Lingjie, Chen Dong. Clinical application of nutritional support on mechanical ventilation in acute exacerbation of chronic obstructive pulmonary disease [J]. Clinical Focus, 2022, 37(6): 510-514.
[6]	. [J]. Clinical Focus, 2021, 36(9): 861-864.
[7]	Fu Qun, Guo Di, Zhao Wenfei. VEGF, ICAM-1, IL-13, FeNO level of induced sputum on asthma, asthma-copd overlap, and chronic obstructive pulmonary disease in patients: clinical changes and significance [J]. Clinical Focus, 2021, 36(6): 513-516.
[8]	Zhang Qinxia, a, Zhang Haifu, b, Lyu Quna. Efficacy and safety of ticagrelor in coronary artery disease and chronic obstructive pulmonary disease: a metaanalysis [J]. Clinical Focus, 2020, 35(11): 965-970.
[9]	. [J]. Clinical Focus, 2016, 31(3): 345-348.
[10]	Lu Qiuxia;Chen Xi;Wu Xiao;Hu Shanyou;Wang Li. Plasma N-terminal B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease patients and prognosis [J]. Clinical Focus, 2015, 30(11): 1265-1268.
[11]	. [J]. Clinical Focus, 2015, 30(9): 1063-1066.
[12]	. @@ [J]. Clinical Focus, 2015, 30(8): 956-960.
[13]	Zhang Zhen;Jia Shiqiang;Peng Zhanxian;Zong Wei;Wen Shiwei;Sun Luhua;Rong Xuebing;Wang Jingjun;Dong Shimin. Clinical value of rapid shallow breathing index in predicting ventilator weaning in sleeping patients with acute exacerbation chronic obstructive pulmonary disease [J]. Clinical Focus, 2015, 30(5): 506-508509.
[14]	. [J]. Clinical Focus, 2015, 30(5): 564-566.
[15]	Hu Shanshan;Zhang Shun;Cai Ting. Immunochemotherapy for advanced non-small cell lung cancer:a meta-analysis [J]. Clinical Focus, 2015, 30(3): 283-289.